Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients
Identifieur interne : 001E77 ( Main/Exploration ); précédent : 001E76; suivant : 001E78Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients
Auteurs : J. Wenzel [Allemagne] ; S. Br Hler [Allemagne] ; R. Bauer [Allemagne] ; T. Bieber [Allemagne] ; T. Tüting [Allemagne]Source :
- British Journal of Dermatology [ 0007-0963 ] ; 2005-07.
English descriptors
- Teeft :
- Adverse reactions, British association, Clai, Cutaneous, Cutaneous lesions, Cutaneous lupus activation index, Cutaneous lupus erythematosus, Dermatol, Dermatologists british journal, Dermatology, Disease activity, Erythematosus, Gastrointestinal tract, Lesion, Liver enzymes, Lupus, Lupus erythematosus, Lymphocyte, Methotrexate, Methotrexate treatment, Mycophenolate mofetil, Peripheral lymphocyte numbers, Scle, Skin involvement, Skin lesions, Subacute, Subacute cutaneous lupus erythematosus, Systemic, Wenzel.
Abstract
Background The therapy of cutaneous lupus erythematosus (CLE) is often challenging, especially in patients resistant to topical treatment and established first‐line systemic drugs such as antimalarials. Systemic corticosteroids are effective, but their use is limited due to well‐known side‐effects, especially in long‐term treatment. In recent years several other immunosuppressive agents have been successfully applied in CLE. However, there are no large studies or explicit guidelines on the use of these drugs in CLE. Objectives To perform a retrospective investigation of the efficacy of low‐dose methotrexate (MTX) in the treatment of CLE. Methods One hundred and thirty‐nine patients with CLE were seen at our department between 2001 and 2003, of whom 43 patients required low‐dose MTX. All had histologically confirmed CLE lesions. Clinical data including disease activity, additional treatment, laboratory parameters and side‐effects were recorded carefully at the time of presentation. Statistical analyses were performed by paired nonparametric Wilcoxon test and Student's t‐test using SPSS 11 software. Results MTX led to a highly significant (P < 0·01) decline in disease activity. An improvement of the cutaneous lesions was recorded in nearly all patients treated with MTX (42 of 43; 98%). Severe side‐effects necessitating discontinuation of MTX treatment were recorded in seven patients (16%), which quickly resolved when MTX was discontinued. Life‐threatening complications were not observed. Intravenous application was tolerated better than oral administration. Interestingly, we observed a significant increase in circulating lymphocyte numbers in patients with lymphopenia (< 1·0 × 109 cells L−1) prior to MTX treatment. Conclusions Our study supports earlier findings reporting the efficacy of low‐dose MTX in CLE lesions, particularly in recalcitrant clinical courses. MTX treatment appears to be safe if patients are carefully selected and monitored, with particular attention to side‐effects and contraindications.
Url:
DOI: 10.1111/j.1365-2133.2005.06552.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000368
- to stream Istex, to step Curation: 000368
- to stream Istex, to step Checkpoint: 000D27
- to stream Main, to step Merge: 001E91
- to stream Main, to step Curation: 001E77
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients</title>
<author><name sortKey="Wenzel, J" sort="Wenzel, J" uniqKey="Wenzel J" first="J." last="Wenzel">J. Wenzel</name>
</author>
<author><name sortKey="Br Hler, S" sort="Br Hler, S" uniqKey="Br Hler S" first="S." last="Br Hler">S. Br Hler</name>
</author>
<author><name sortKey="Bauer, R" sort="Bauer, R" uniqKey="Bauer R" first="R." last="Bauer">R. Bauer</name>
</author>
<author><name sortKey="Bieber, T" sort="Bieber, T" uniqKey="Bieber T" first="T." last="Bieber">T. Bieber</name>
</author>
<author><name sortKey="Tuting, T" sort="Tuting, T" uniqKey="Tuting T" first="T." last="Tüting">T. Tüting</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BA646AF3C2195E75255EA26C5BF7345AC9F075FD</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1111/j.1365-2133.2005.06552.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-8128R7BJ-Z/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000368</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000368</idno>
<idno type="wicri:Area/Istex/Curation">000368</idno>
<idno type="wicri:Area/Istex/Checkpoint">000D27</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D27</idno>
<idno type="wicri:doubleKey">0007-0963:2005:Wenzel J:efficacy:and:safety</idno>
<idno type="wicri:Area/Main/Merge">001E91</idno>
<idno type="wicri:Area/Main/Curation">001E77</idno>
<idno type="wicri:Area/Main/Exploration">001E77</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients</title>
<author><name sortKey="Wenzel, J" sort="Wenzel, J" uniqKey="Wenzel J" first="J." last="Wenzel">J. Wenzel</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University of Bonn, Sigmund‐Freud‐Strasse 25, 53105 Bonn</wicri:regionArea>
<placeName><settlement type="city">Bonn</settlement>
<region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Br Hler, S" sort="Br Hler, S" uniqKey="Br Hler S" first="S." last="Br Hler">S. Br Hler</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University of Bonn, Sigmund‐Freud‐Strasse 25, 53105 Bonn</wicri:regionArea>
<placeName><settlement type="city">Bonn</settlement>
<region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bauer, R" sort="Bauer, R" uniqKey="Bauer R" first="R." last="Bauer">R. Bauer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University of Bonn, Sigmund‐Freud‐Strasse 25, 53105 Bonn</wicri:regionArea>
<placeName><settlement type="city">Bonn</settlement>
<region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bieber, T" sort="Bieber, T" uniqKey="Bieber T" first="T." last="Bieber">T. Bieber</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University of Bonn, Sigmund‐Freud‐Strasse 25, 53105 Bonn</wicri:regionArea>
<placeName><settlement type="city">Bonn</settlement>
<region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tuting, T" sort="Tuting, T" uniqKey="Tuting T" first="T." last="Tüting">T. Tüting</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University of Bonn, Sigmund‐Freud‐Strasse 25, 53105 Bonn</wicri:regionArea>
<placeName><settlement type="city">Bonn</settlement>
<region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">British Journal of Dermatology</title>
<title level="j" type="alt">BRITISH JOURNAL OF DERMATOLOGY</title>
<idno type="ISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<imprint><biblScope unit="vol">153</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="157">157</biblScope>
<biblScope unit="page" to="162">162</biblScope>
<biblScope unit="page-count">6</biblScope>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-07">2005-07</date>
</imprint>
<idno type="ISSN">0007-0963</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0007-0963</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse reactions</term>
<term>British association</term>
<term>Clai</term>
<term>Cutaneous</term>
<term>Cutaneous lesions</term>
<term>Cutaneous lupus activation index</term>
<term>Cutaneous lupus erythematosus</term>
<term>Dermatol</term>
<term>Dermatologists british journal</term>
<term>Dermatology</term>
<term>Disease activity</term>
<term>Erythematosus</term>
<term>Gastrointestinal tract</term>
<term>Lesion</term>
<term>Liver enzymes</term>
<term>Lupus</term>
<term>Lupus erythematosus</term>
<term>Lymphocyte</term>
<term>Methotrexate</term>
<term>Methotrexate treatment</term>
<term>Mycophenolate mofetil</term>
<term>Peripheral lymphocyte numbers</term>
<term>Scle</term>
<term>Skin involvement</term>
<term>Skin lesions</term>
<term>Subacute</term>
<term>Subacute cutaneous lupus erythematosus</term>
<term>Systemic</term>
<term>Wenzel</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background The therapy of cutaneous lupus erythematosus (CLE) is often challenging, especially in patients resistant to topical treatment and established first‐line systemic drugs such as antimalarials. Systemic corticosteroids are effective, but their use is limited due to well‐known side‐effects, especially in long‐term treatment. In recent years several other immunosuppressive agents have been successfully applied in CLE. However, there are no large studies or explicit guidelines on the use of these drugs in CLE. Objectives To perform a retrospective investigation of the efficacy of low‐dose methotrexate (MTX) in the treatment of CLE. Methods One hundred and thirty‐nine patients with CLE were seen at our department between 2001 and 2003, of whom 43 patients required low‐dose MTX. All had histologically confirmed CLE lesions. Clinical data including disease activity, additional treatment, laboratory parameters and side‐effects were recorded carefully at the time of presentation. Statistical analyses were performed by paired nonparametric Wilcoxon test and Student's t‐test using SPSS 11 software. Results MTX led to a highly significant (P < 0·01) decline in disease activity. An improvement of the cutaneous lesions was recorded in nearly all patients treated with MTX (42 of 43; 98%). Severe side‐effects necessitating discontinuation of MTX treatment were recorded in seven patients (16%), which quickly resolved when MTX was discontinued. Life‐threatening complications were not observed. Intravenous application was tolerated better than oral administration. Interestingly, we observed a significant increase in circulating lymphocyte numbers in patients with lymphopenia (< 1·0 × 109 cells L−1) prior to MTX treatment. Conclusions Our study supports earlier findings reporting the efficacy of low‐dose MTX in CLE lesions, particularly in recalcitrant clinical courses. MTX treatment appears to be safe if patients are carefully selected and monitored, with particular attention to side‐effects and contraindications.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>District de Cologne</li>
<li>Rhénanie-du-Nord-Westphalie</li>
</region>
<settlement><li>Bonn</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Wenzel, J" sort="Wenzel, J" uniqKey="Wenzel J" first="J." last="Wenzel">J. Wenzel</name>
</region>
<name sortKey="Bauer, R" sort="Bauer, R" uniqKey="Bauer R" first="R." last="Bauer">R. Bauer</name>
<name sortKey="Bieber, T" sort="Bieber, T" uniqKey="Bieber T" first="T." last="Bieber">T. Bieber</name>
<name sortKey="Br Hler, S" sort="Br Hler, S" uniqKey="Br Hler S" first="S." last="Br Hler">S. Br Hler</name>
<name sortKey="Tuting, T" sort="Tuting, T" uniqKey="Tuting T" first="T." last="Tüting">T. Tüting</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:BA646AF3C2195E75255EA26C5BF7345AC9F075FD |texte= Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients }}
This area was generated with Dilib version V0.6.33. |